{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:53:22Z","timestamp":1793066002346,"version":"4.5.0"},"reference-count":212,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015756","name":"Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.trre.2024.100875","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:08:22Z","timestamp":1722888502000},"page":"100875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update"],"prefix":"10.1016","volume":"38","author":[{"given":"Elisa","family":"Ruiz-Arabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Torre-Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bodro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cantis\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Cast\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Facundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian","family":"Fern\u00e1ndez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Fort\u00fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dolores","family":"Garc\u00eda-Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Iturbe-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Len","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"L\u00f3pez-Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Ovidia","family":"L\u00f3pez-Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibai","family":"Los-Arcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Mart\u00edn-D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"P\u00e1ez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodr\u00edguez","family":"\u00c1lvarez R.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rodr\u00edguez-Benot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rodr\u00edguez-Goncer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"San-Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"S\u00e1nchez-C\u00e9spedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricela","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Vaquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Viasus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2024.100875_bb0005","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the Management of Cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0010","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2024.100875_bb0015","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/bmj.39504.506319.80","article-title":"Incorporating considerations of resources use into grading recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2024.100875_bb0020","doi-asserted-by":"crossref","first-page":"a744","DOI":"10.1136\/bmj.a744","article-title":"Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive","volume":"337","author":"Jaeschke","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2024.100875_bb0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2024.100875_bb0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trre.2016.04.001","article-title":"Management of cytomegalovirus infection in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations","volume":"30","author":"Torre-Cisneros","year":"2016","journal-title":"Transplant Rev"},{"key":"10.1016\/j.trre.2024.100875_bb0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.diagmicrobio.2018.11.012","article-title":"Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients","volume":"94","author":"Vinuesa","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2023.105582","article-title":"Assessment of an automated cytomegalovirus nucleic acid amplification test using clinical plasma, bronchoalveolar lavage, and tissue specimens","volume":"168","author":"Huang","year":"2023","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2024.100875_bb0045","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1038\/s41598-020-60655-6","article-title":"High-resolution profiling of human cytomegalovirus cell-free DNA in human plasma highlights its exceptionally fragmented nature","volume":"10","author":"Peddu","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.trre.2024.100875_bb0050","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cid\/ciw608","article-title":"Would kinetic analyses of plasma cytomegalovirus DNA load help to reach consensus criteria for triggering the initiation of preemptive antiviral therapy in transplant recipients?","volume":"63","author":"Vinuesa","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0055","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","volume":"12","author":"Atabani","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163722","article-title":"Randomized controlled trials to define viral load thresholds for cytomegalovirus pre-emptive therapy","volume":"11","author":"Griffiths","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.trre.2024.100875_bb0065","first-page":"20","article-title":"Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: a pilot study","author":"Mart\u00edn-Gandul","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0080","first-page":"21","article-title":"Comparison of universal prophylaxis and preemptive approach for cytomegalovirus associated outcome measures in renal transplant patients: a meta-analysis of available data","author":"Caskurlu","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0085","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1681\/ASN.0000000000000090","article-title":"A randomized trial of Valganciclovir prophylaxis versus preemptive therapy in kidney transplant recipients","volume":"34","author":"Reischig","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100875_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2020.100587","article-title":"Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: a systematic review of randomized controlled trials","volume":"35","author":"Raval","year":"2021","journal-title":"Transplant Rev"},{"key":"10.1016\/j.trre.2024.100875_bb0095","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001514","article-title":"A systematic review and Meta-analysis of optimized CMV preemptive therapy and antiviral prophylaxis for CMV disease prevention in CMV high-risk (D+R-) kidney transplant recipients","volume":"9","author":"Kumar","year":"2023","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2024.100875_bb0100","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1097\/TP.0000000000004615","article-title":"Cytomegalovirus high-risk kidney transplant recipients show no difference in long-term outcomes following preemptive versus prophylactic management","volume":"107","author":"Blom","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0205","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs Valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2024.100875_bb0965","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days Valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0970","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended Valganciclovir prophylaxis in D+\/R\u2212 kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0465","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0490","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0495","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0500","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12879-018-3075-z","article-title":"Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients","volume":"18","author":"Deborska-Materkowska","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0515","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015228","article-title":"Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: a PRISMA-compliant article","volume":"98","author":"Ruan","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.trre.2024.100875_bb0530","article-title":"Immune monitoring-guided vs fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients. A multicenter, randomized Clinical Trial","author":"Manuel","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0580","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1128\/JCM.00563-13","article-title":"Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients","volume":"51","author":"Abate","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trre.2024.100875_bb0975","first-page":"561","article-title":"Effect of delaying prophylaxis against CMV in D+\/R- solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease","volume":"71","author":"San-Juan","year":"2015","journal-title":"J Inf Secur"},{"key":"10.1016\/j.trre.2024.100875_bb0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0075","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/TP.0000000000002024","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial","volume":"102","author":"Witzke","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0480","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/cid\/ciz1209","article-title":"Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: a prospective, interventional","volume":"71","author":"Jarque","year":"2020","journal-title":"Multicenter Clin Trial Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0485","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/ajt.12256","article-title":"Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation","volume":"13","author":"Bestard","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0540","doi-asserted-by":"crossref","first-page":"381.e1","DOI":"10.1016\/j.cmi.2018.05.010","article-title":"Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment","volume":"25","author":"Fern\u00e1ndez-Ruiz","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2024.100875_bb0545","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/ajt.13012","article-title":"Factors related to the development of CMV-specific CD8+ T cell response in CMV-seropositive solid organ transplant candidates","volume":"15","author":"Cantis\u00e1n","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0550","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant interferon-\u03b3 secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation","volume":"13","author":"Cantis\u00e1n","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0555","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.TP.0000438025.96334.eb","article-title":"Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant","volume":"97","author":"L\u00f3pez-Oliva","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0980","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/TP.0000000000000030","article-title":"Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation","volume":"98","author":"Santos","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0985","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/tid.12227","article-title":"Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients","volume":"16","author":"Lee","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0990","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/tri.12616","article-title":"ABO desensitization affects cellular immunity and infection control after renal transplantation","volume":"28","author":"Schachtner","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100875_bb0995","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5414\/CN109114","article-title":"Successful launch of an ABO-incompatible kidney transplantation program to overcome the shortage of compatible living donors: experience at a single center","volume":"88","author":"Song","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.trre.2024.100875_bb1000","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000004789","article-title":"A multicenter retrospective cohort study on management protocols and clinical outcomes after ABO-incompatible kidney transplantation in India","author":"Kute","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0535","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/cid\/ciab574","article-title":"Immunoguided discontinuation of prophylaxis for cytomegalovirus disease in kidney transplant recipients treated with antithymocyte globulin: a randomized clinical trial","volume":"74","author":"P\u00e1ez-Vega","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0105","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2024.100875_bb0110","article-title":"Association of CMV DNAemia with long-term mortality in a randomized trial of preemptive therapy (PET) and antiviral prophylaxis (AP) for prevention of CMV disease in high-risk donor seropositive, recipient seronegative (D+R-) liver transplant recipients","author":"Kumar","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0115","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/ajt.13044","article-title":"Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and Meta-analysis","volume":"15","author":"Mumtaz","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0120","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/cit945","article-title":"A direct and indirect comparison Meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant","volume":"58","author":"Florescu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953210","article-title":"Antiviral prophylaxis or preemptive therapy for cytomegalovirus after liver transplantation?: a systematic review and meta-analysis","volume":"13","author":"Yadav","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2024.100875_bb0130","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14631","article-title":"What is the optimal antimicrobial prophylaxis to prevent postoperative infectious complications after liver transplantation? A systematic review of the literature and expert panel recommendations","volume":"36","author":"Campos-Varela","year":"2022","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0505","first-page":"9","article-title":"Comparison of three cellular assays to predict the course of CMV infection in liver transplant recipients","author":"Gliga","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.trre.2024.100875_bb1005","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14011","article-title":"Role of cytomegalovirus specific cell-mediated immunity in the monitoring of cytomegalovirus infection among living donor liver transplantation adult recipients: a single-center experience","volume":"25","author":"Bhugra","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb1010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2018.05.006","article-title":"Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG+ response","volume":"155","author":"P\u00e1ez-Vega","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trre.2024.100875_bb0145","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/ajt.12388","article-title":"Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients","volume":"13","author":"Manuel","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0150","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1111\/ajt.15371","article-title":"Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients","volume":"19","author":"L\u2019Huillier","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb1015","first-page":"22","article-title":"Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive\/recipient seronegative heart transplant recipients","author":"Imlay","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0560","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1097\/TP.0000000000001825","article-title":"CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor","volume":"101","author":"Schachtner","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0155","first-page":"37","article-title":"Incidence and severity of cytomegalovirus infection in seropositive heart transplant recipients","author":"Gardiner","year":"2023","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0160","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15065","article-title":"Multicenter study of universal prophylaxis versus pre-emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation","volume":"37","author":"Lerman","year":"2023","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0510","first-page":"56","article-title":"Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: clinical utility of the QuantiFERON-CMV assay for Management of Posttransplant CMV infection","author":"Chiereghin","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trre.2024.100875_bb0175","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-152-12-201006150-00003","article-title":"Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial","volume":"152","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2024.100875_bb0180","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.healun.2009.03.012","article-title":"Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy","volume":"28","author":"Jaksch","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0185","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.healun.2011.02.017","article-title":"Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial","volume":"30","author":"Finlen Copeland","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb1020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1600-6143.2012.04339.x","article-title":"Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV Serostatus guide the duration of prophylaxis?","volume":"13","author":"Schoeppler","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb1025","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/j.1600-6143.2011.03663.x","article-title":"Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome","volume":"11","author":"Paraskeva","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0165","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A randomized study of Quantiferon CMV-directed versus fixed-duration Valganciclovir prophylaxis to reduce late CMV after lung transplantation","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0525","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.healun.2022.05.004","article-title":"Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients","volume":"41","author":"Gardiner","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb1030","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1600-6143.2009.02574.x","article-title":"A multicenter study of Valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients","volume":"9","author":"Monforte","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb1035","first-page":"19","article-title":"Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: a prospective, observational, multicenter study","author":"Monforte","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0520","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/infdis\/jiaa727","article-title":"CMV-specific cell-mediated immunity predicts a high level of CMV replication after prophylaxis withdrawal in lung transplant recipients","volume":"224","author":"Donadeu","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb1040","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.arbres.2021.10.002","article-title":"Assessment of Quantiferon\u00ae-CMV and Immuknow\u00ae assays in CMV-seropositive lung transplant recipients to stratify risk of CMV infection","volume":"58","author":"Monforte","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.trre.2024.100875_bb1045","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.21037\/jtd-23-48","article-title":"ABO blood type incompatible lung transplantation","volume":"15","author":"Chen-Yoshikawa","year":"2023","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0190","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.transproceed.2015.09.070","article-title":"Cytomegalovirus infection and rates of antiviral resistance following intestinal and multivisceral transplantation","volume":"48","author":"Ambrose","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100875_bb0195","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/TP.0000000000000832","article-title":"Cytomegalovirus infection after intestinal\/multivisceral transplantation: a single-center experience with 210 cases","volume":"100","author":"Nagai","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0200","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/ajt.12013","article-title":"Infections following facial composite tissue Allotransplantation\u2014single center experience and review of the literature","volume":"13","author":"Knoll","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb1050","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ctr.12138","article-title":"Cytomegalovirus infection post-pancreas\u2013kidney transplantation \u2013 results of antiviral prophylaxis in high-risk patients","volume":"27","author":"Fallatah","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb1055","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2008111166","article-title":"Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection","volume":"20","author":"Luan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100875_bb1060","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1399-3062.2009.00416.x","article-title":"Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas\u2013kidney transplant recipients","volume":"11","author":"L\u00f3pez-Medrano","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0475","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0610","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.transproceed.2019.11.002","article-title":"Monitoring of CMV-specific cell-mediated immunity in kidney transplant recipients with a high risk of CMV disease (D+\/R-): a case series","volume":"52","author":"Andreani","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100875_bb0135","first-page":"25","article-title":"Real-world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high-risk donor seropositive\/recipient seronegative (D+R-) liver transplant recipients (LTxR)","author":"Doss","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0140","doi-asserted-by":"crossref","first-page":"e2739","DOI":"10.1093\/cid\/ciaa1051","article-title":"Cost-effectiveness of preemptive therapy versus prophylaxis in a randomized clinical trial for the prevention of cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors","volume":"73","author":"Singh","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030648","article-title":"Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial","volume":"9","author":"Paez-Vega","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.trre.2024.100875_bb0210","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0b013e31828ee12e","article-title":"International survey of cytomegalovirus Management in Solid Organ Transplantation after the publication of consensus guidelines","volume":"95","author":"Le Page","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0215","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.transproceed.2021.05.006","article-title":"Efficacy and safety according to the dose of Valganciclovir for cytomegalovirus prophylaxis in transplantation: network meta-analysis using recent data","volume":"53","author":"Lee","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100875_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13713","article-title":"Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients","volume":"23","author":"Bixby","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0225","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","volume":"17","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0230","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving Everolimus and reduced tacrolimus doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0235","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0240","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/tri.12848","article-title":"Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis","volume":"29","author":"Cervera","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100875_bb0245","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/ajt.16946","article-title":"Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: a randomized, open-label, multicenter phase 4 trial","volume":"22","author":"Kaminski","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0250","first-page":"1835","article-title":"Conversion to mTOR inhibitor to reduce the incidence of cytomegalovirus recurrence in kidney transplant recipients receiving preemptive treatment: a prospective","volume":"107","author":"Viana","year":"2023","journal-title":"Randomiz Trial Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0255","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":"Everolimus versus mycophenolate Mofetil in heart transplantation: a randomized","volume":"13","author":"Eisen","year":"2013","journal-title":"Multicenter Trial Am J Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0260","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/tid.12007","article-title":"Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation","volume":"15","author":"Kobashigawa","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0265","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10741-020-09967-3","article-title":"Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens","volume":"27","author":"Ueyama","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.trre.2024.100875_bb0270","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.healun.2013.04.010","article-title":"Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation","volume":"32","author":"Ghassemieh","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0275","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1681\/ASN.2020121753","article-title":"mTOR inhibitors prevent CMV infection through the restoration of functional \u03b1\u03b2 and \u03b3\u03b4 T cells in kidney transplantation","volume":"33","author":"Kaminski","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100875_bb0280","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0285","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/iid3.508","article-title":"Cytomegalovirus mismatch after heart transplantation: impact of antiviral prophylaxis and intravenous hyperimmune globulin","volume":"9","author":"Immohr","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0290","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1034\/j.1399-3062.2001.00010.x","article-title":"Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation","volume":"3","author":"Zamora","year":"2001","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0295","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/j.transproceed.2016.07.039","article-title":"Potential immunomodulatory role of specific Anticytomegalovirus intravenous immunoglobulin in heart recipients","volume":"48","author":"Carbone","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100875_bb0300","doi-asserted-by":"crossref","first-page":"438","DOI":"10.23736\/S0031-0808.22.04736-X","article-title":"Keep on tailoring CMV management in lung transplantation: 24 versus 12-month CMV hyperimmune globulins regimen effects in combined universal prophylaxis","volume":"64","author":"Solidoro","year":"2022","journal-title":"Panminerva Med"},{"key":"10.1016\/j.trre.2024.100875_bb0305","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/tid.12593","article-title":"Hypogammaglobulinemia and risk of severe infection in kidney transplant recipients","volume":"18","author":"Augusto","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0310","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1399-0012.2010.01255.x","article-title":"Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon?","volume":"25","author":"Boddana","year":"2011","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0315","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-0012.2007.00750.x","article-title":"CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis","volume":"22","author":"Bonaros","year":"2008","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0320","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1053-2498(00)00331-4","article-title":"Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection","volume":"20","author":"Yamani","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0325","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1034\/j.1399-3062.2001.00008.x","article-title":"Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes","volume":"3","author":"Yamani","year":"2001","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0330","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.healun.2004.11.016","article-title":"The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study","volume":"24","author":"Yamani","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0335","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/tid.12610","article-title":"Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial","volume":"18","author":"Sarmiento","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0340","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/cid\/ciy295","article-title":"Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"67","author":"Gardiner","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0345","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/TP.0000000000004360","article-title":"Absolute lymphocyte count as a marker for cytomegalovirus infection after heart transplantation","volume":"107","author":"Schoeberl","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0350","first-page":"5","article-title":"Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation","author":"Meesing","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0355","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/tid.12564","article-title":"Post-transplant monitoring of NK cell counts as a simple approach to predict the occurrence of opportunistic infection in liver transplant recipients","volume":"18","author":"Fern\u00e1ndez-Ruiz","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0360","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/tri.12321","article-title":"Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation","volume":"27","author":"Fern\u00e1ndez-Ruiz","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100875_bb0365","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jcv.2015.06.078","article-title":"T-lymphocyte subsets in lung transplant recipients: association between nadir CD4 T-cell count and viral infections after transplantation","volume":"69","author":"Calarota","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2024.100875_bb0370","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/infdis\/jiaa090","article-title":"A new clinical and Immunovirological score for predicting the risk of late severe infection in solid organ transplant recipients: the CLIV score","volume":"222","author":"San-Juan","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0375","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.kint.2020.04.054","article-title":"Derivation and external validation of the SIMPLICITY score as a simple immune-based risk score to predict infection in kidney transplant recipients","volume":"98","author":"Fern\u00e1ndez-Ruiz","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100875_bb0380","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/tid.12284","article-title":"Evaluation of an immunological score to assess the risk of severe infection in heart recipients","volume":"16","author":"Sarmiento","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0385","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/01.tp.0000180531.66518.9e","article-title":"Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes","volume":"81","author":"Doron","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0390","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/ejcts\/ezt583","article-title":"Effect of hypogammaglobulinemia after lung transplantation: a single-institution study","volume":"45","author":"Ohsumi","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.trre.2024.100875_bb0395","doi-asserted-by":"crossref","first-page":"E289","DOI":"10.1111\/ctr.12116","article-title":"Hypogammaglobulinemia in the early period after liver transplantation in children","volume":"27","author":"Mozer-Glassberg","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0400","first-page":"19","article-title":"Post-transplant hypogammaglobulinemia and risk of infection after kidney transplantation: magnitude matters","author":"Fern\u00e1ndez-Ruiz","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0405","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13494","article-title":"Secondary antibody deficiency is associated with development of infection in kidney transplantation: results of a multicenter study","volume":"23","author":"Sarmiento","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0410","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13587","article-title":"AST infectious diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation infectious diseases Community of Practice","volume":"33","author":"Fishman","year":"2019","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0415","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.healun.2007.07.010","article-title":"Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer?","volume":"26","author":"Mu\u00f1oz","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0420","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MOT.0b013e3283186bbc","article-title":"Hypogammaglobulinemia and infection risk in solid organ transplant recipients","volume":"13","author":"Mawhorter","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0425","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.healun.2016.10.004","article-title":"Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: a multicenter prospective study","volume":"36","author":"Sarmiento","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0430","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14087","article-title":"Hypogammaglobulinemia following heart transplantation: prevalence, predictors, and clinical importance","volume":"34","author":"Fujino","year":"2020","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0435","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4285\/kjt.22.0001","article-title":"Laboratory diagnostic testing for cytomegalovirus infection in solid organ transplant patients","volume":"36","author":"Lee","year":"2022","journal-title":"Korean J Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0440","article-title":"Post-transplant dynamics and clinical significance of CMV-specific neutralizing antibodies in kidney transplant recipients treated with T-cell-depleting agents","author":"Fern\u00e1ndez-Ruiz","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102185","article-title":"T cell immunity to cytomegalovirus infection","volume":"77","author":"Zangger","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.trre.2024.100875_bb0450","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1128\/jvi.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.trre.2024.100875_bb0455","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12879-020-4787-4","article-title":"Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events","volume":"20","author":"Rogers","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0460","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1111\/j.1600-6143.2006.01488.x","article-title":"Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation","volume":"6","author":"Gerna","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0470","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/ajt.15793","article-title":"Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-\u03b3 release assay in kidney transplant recipients treated with antithymocyte globulin","volume":"20","author":"Fern\u00e1ndez-Ruiz","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0605","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1086\/654931","volume":"202","author":"Abate","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb1065","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1111\/j.1600-6143.2012.04076.x","article-title":"Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients","volume":"12","author":"Weseslindtner","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0585","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1399-0012.2009.00976.x","article-title":"CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study","volume":"24","author":"Sund","year":"2010","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0590","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1600-6143.2011.03636.x","article-title":"Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation","volume":"11","author":"Gerna","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0595","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1479-5876-6-29","article-title":"Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients","volume":"6","author":"Egli","year":"2008","journal-title":"J Transl Med"},{"key":"10.1016\/j.trre.2024.100875_bb0600","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1097\/00007890-200105150-00018","article-title":"Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation","volume":"71","author":"Sester","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0615","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.893232","article-title":"QuantiFERON-cytomegalovirus assay for prediction of cytomegalovirus viremia in kidney transplant recipients: study from high cytomegalovirus Seroprevalence country","volume":"12","author":"Pongsakornkullachart","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.trre.2024.100875_bb0575","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/infdis\/jir624","article-title":"Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients","volume":"204","author":"Pipeling","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0570","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0565","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/cid\/ciu589","article-title":"Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients","volume":"59","author":"L\u00facia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0620","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-virology-100220-010653","article-title":"Lessons from acquired natural immunity and clinical trials to inform next-generation human cytomegalovirus vaccine development","volume":"9","author":"Hu","year":"2022","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.trre.2024.100875_bb0625","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2024.100875_bb0630","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28572","article-title":"mRNA vaccines: the future of prevention of viral infections?","volume":"95","author":"Rzymski","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.trre.2024.100875_bb0635","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1086\/444398","article-title":"A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients","volume":"192","author":"Humar","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0640","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/523590","article-title":"Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients","volume":"46","author":"Len","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0645","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1399-3062.2009.00481.x","article-title":"Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics","volume":"12","author":"Cald\u00e9s","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0650","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0655","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1016\/j.transproceed.2006.10.105","article-title":"Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients","volume":"38","author":"Luan","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100875_bb0660","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2009.02617.x","article-title":"Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients","volume":"9","author":"Asberg","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0665","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2002.126306","article-title":"Pharmacokinetics of valganciclovir and ganciclovir in renal impairment","volume":"72","author":"Czock","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.trre.2024.100875_bb0670","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40262-023-01237-3","article-title":"Comparison of three renal function formulas for ganciclovir\/Valganciclovir dose individualization in CMV-infected solid organ transplantation patients using a population approach","volume":"62","author":"Lalagkas","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2024.100875_bb0675","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13687","article-title":"Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0680","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of Oral Brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0685","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005226","article-title":"Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection","volume":"95","author":"Faure","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.trre.2024.100875_bb0690","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.medmal.2018.03.006","article-title":"Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections","volume":"48","author":"Frange","year":"2018","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.trre.2024.100875_bb0695","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1128\/AAC.48.12.4745-4753.2004","article-title":"Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2024.100875_bb0700","first-page":"64","article-title":"Filociclovir is a potent in vitro and in vivo inhibitor of human adenoviruses","author":"Toth","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2024.100875_bb0705","first-page":"63","article-title":"Phase Ib trial to evaluate the safety and pharmacokinetics of multiple ascending doses of Filociclovir (MBX-400, Cyclopropavir) in healthy volunteers","author":"Rouphael","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2024.100875_bb0710","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.tim.2022.12.003","article-title":"Novel monoclonal antibody-based therapies: implications for the treatment and prevention of HCMV disease","volume":"31","author":"Nu\u00e9valos","year":"2023","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.trre.2024.100875_bb0715","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1399-3062.2009.00443.x","article-title":"Relapsing cytomegalovirus infection in solid organ transplant recipients","volume":"11","author":"Shanahan","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0720","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-6143.2009.02861.x","article-title":"Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients","volume":"10","author":"Eid","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0725","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cix793","article-title":"Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis","volume":"66","author":"Natori","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0730","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/cid\/cix696","article-title":"Role of secondary prophylaxis with Valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"65","author":"Gardiner","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0735","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/TP.0000000000000386","article-title":"The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients","volume":"99","author":"Sullivan","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0740","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/TP.0000000000001338","article-title":"Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients","volume":"101","author":"Natori","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0745","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/cid\/ciy295","article-title":"Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"67","author":"Gardiner","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0750","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1432-2277.2011.01321.x","article-title":"The risk of cytomegalovirus recurrence after kidney transplantation","volume":"24","author":"Helanter\u00e4","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100875_bb0755","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105623","article-title":"Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients","volume":"215","author":"Kleiboeker","year":"2023","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trre.2024.100875_bb0770","first-page":"35","article-title":"Cytomegalovirus Management in Solid Organ Transplant Recipients: a pre-COVID-19 survey from the working Group of the European Society for organ transplantation","author":"Grossi","year":"2022","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100875_bb0775","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.trre.2024.100875_bb0780","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0785","first-page":"36","article-title":"Factors associated with genotypic resistance and outcome among solid organ transplant recipients with refractory cytomegalovirus infection","author":"Tamzali","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2024.100875_bb0790","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2024.100875_bb0795","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2011.01.004","article-title":"Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy","volume":"50","author":"Chou","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2024.100875_bb0800","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trre.2024.100875_bb0805","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13515","article-title":"Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: a case series and review of the literature","volume":"23","author":"Hofmann","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trre.2024.100875_bb0815","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcv.2017.03.014","article-title":"Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance","volume":"90","author":"L\u00f3pez-Aladid","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2024.100875_bb0820","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV Management in Solid Organ Transplant Patients: prevention, treatment, and Management of Resistant\/refractory disease","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.trre.2024.100875_bb0825","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/infdis\/jiz642","article-title":"De novo genotypic heterogeneity in the UL56 region in cytomegalovirus-infected tissues: implications for primary Letermovir resistance","volume":"221","author":"Jo","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0830","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1128\/JCM.01605-13","article-title":"Detection of cytomegalovirus drug resistance mutations by next-generation sequencing","volume":"51","author":"Sahoo","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trre.2024.100875_bb0835","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/infdis\/jiac349","article-title":"Genotypic and phenotypic study of antiviral resistance mutations in refractory cytomegalovirus infection","volume":"226","author":"Santos Bravo","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0840","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/jit654","article-title":"Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial","volume":"209","author":"Chou","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0845","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/TP.0b013e31828555ac","article-title":"Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations","volume":"95","author":"Gracia-Ahufinger","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0850","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with Foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100875_bb0855","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0860","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0865","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0870","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of Maribavir for treatment of cytomegalovirus infection","volume":"226","author":"Chou","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0875","first-page":"256","article-title":"Subcutaneous immunoglobulin replacement therapy in a heart transplant recipient with severe recurrent infections","volume":"7","author":"Carbone","year":"2015","journal-title":"Heart Lung Vessel"},{"key":"10.1016\/j.trre.2024.100875_bb0880","doi-asserted-by":"crossref","first-page":"E277","DOI":"10.1111\/j.1399-0012.2012.01653.x","article-title":"Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections","volume":"26","author":"Carbone","year":"2012","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100875_bb0885","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/340101","article-title":"Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients","volume":"34","author":"Mylonakis","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0890","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.intimp.2004.09.006","article-title":"Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease","volume":"5","author":"Sarmiento","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.trre.2024.100875_bb0895","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13733","article-title":"Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review","volume":"24","author":"Santhanakrishnan","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0900","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100875_bb0905","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100875_bb0910","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fimmu.2020.00271","article-title":"Characterization of a cytomegalovirus-specific T lymphocyte product obtained through a rapid and scalable production process for use in adoptive immunotherapy","volume":"11","author":"Grau-Vorster","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2024.100875_bb0915","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/QCO.0000000000000375","article-title":"Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options","volume":"30","author":"Fuji","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0920","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trre.2024.100875_bb0925","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.3390\/v14112370","article-title":"Adoptive immunotherapy for prophylaxis and treatment of cytomegalovirus infection","volume":"14","author":"Ouellette","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.trre.2024.100875_bb0930","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2024.100875_bb0935","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100875_bb0940","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/ajt.13023","article-title":"Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient","volume":"15","author":"Macesic","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100875_bb0945","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation","volume":"4","author":"Holmes-Liew","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.trre.2024.100875_bb0950","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.oret.2021.04.009","article-title":"Ocular outcomes after treatment of cytomegalovirus retinitis using adoptive immunotherapy with cytomegalovirus-specific cytotoxic T lymphocytes","volume":"5","author":"Gupta","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.trre.2024.100875_bb0955","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100875_bb0960","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2020.09.011","article-title":"CRISPR-Cas9-edited tacrolimus-resistant antiviral T cells for advanced adoptive immunotherapy in transplant recipients","volume":"29","author":"Amini","year":"2021","journal-title":"Mol Ther"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X24000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X24000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T23:00:26Z","timestamp":1737586826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X24000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":212,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0955470X24000582"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2024.100875","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2024.100875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100875"}}